|
Ryasnyansky V.Yu., Shostka G.D., Anikonova L.I.
Nephrogenic anemia in patients receiving renal replacement therapy, pathogenesis and resistance
|
№1 / 2024
|
|
O.N. Vetchinnikova
Modern strategy for erythropoiesis-stimulating therapy in chronic kidney disease
|
№2 / 2016
|
|
N.A. Makarova, Ju.M. Zaharov
Relationship of renal excretory function impairment to serum erythropoietin level in chronic heart failure
|
№1 / 2015
|
|
Without authors
First monograph of E.M. Tareev
|
№1 / 2012
|
|
V.V. Fomin. L.V. Kozlovskaya, Yu.S. Milovanov
Cardiomyopathy in anemia, associated with chronic kidney disease: role of erythropoetin-beta
|
№6 / 2011
|
|
P.A. Vorobyev, L.Yu. Bezmenitsina
Epidemiology and quality of life in patients with chronic renal failire and anemia, receiving programm hemodyalisis. Part 2. Quality of life and costs of erythropoietin treatment
|
№2 / 2011
|
|
A.Yu. Zemchenkov, K.A.Vishnevsky, R.P.Gerasimchuk, S.L.Gavric, T.G.Kostyleva, V.N.Suchkov
The efficacy and safety evaluation of the domestic erythropoietin-β. The review and open multicenter study report
|
№2 / 2011
|
|
P.A. Vorobev, L.J. Bezmelnitsyna
Epidemiology and quality of life in patients with chronic renal failire and anemia, receiving programm hemodyalisis. Part 1. Epidemiology and use of erythropoietin medications
|
№1 / 2011
|
|
Hasabov N.N.
Use of erythropoietin in patients with terminal renal failure, treated with chronic hemodialysis (results of multicenter observational studs)
|
№3 / 2009
|
|
Yu. M. Zakharov (Chelyabinsk)
Citoprotective effects of erythropoietin.
|
№1 / 2009
|
Русский
